MAZE logo

MAZE
Maze Therapeutics Inc.

133
Mkt Cap
$1.43B
Volume
176.00
52W High
$53.65
52W Low
$7.99
PE Ratio
-9.31
MAZE Fundamentals
Price
$26.47
Prev Close
$25.81
Open
$25.72
50D MA
$38.44
Beta
0.96
Avg. Volume
1.16M
EPS (Annual)
-$2.66
P/B
3.68
Rev/Employee
$0.00
$1,725.36
Loading...
Loading...
News
all
press releases
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Here's Why
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Should You Buy...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Maze Therapeutics Prices $150 Mln Stock, Pre-Funded Warrants Offering
(RTTNews) - Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds...
Nasdaq News: Markets·6d ago
News Placeholder
239,994 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Mass General Brigham Inc
Mass General Brigham Inc acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·7d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·10d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume - Here's What Happened
Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume - Here's Why...
MarketBeat·14d ago
News Placeholder
HC Wainwright Issues Optimistic Estimate for MAZE Earnings
Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Research analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for shares of Maze Therapeutics in a research report...
MarketBeat·19d ago
News Placeholder
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
Key PointsChief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026...
Nasdaq News: Markets·24d ago
News Placeholder
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 15,000 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $29.46, for a total value of $441,900.00. Following the sale, the chief marketing...
MarketBeat·26d ago
News Placeholder
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 2,500 Shares of Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 2,500 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total value of $73,600.00. Following the completion of the transaction...
MarketBeat·26d ago
News Placeholder
JPMorgan Chase & Co. Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $58.00
JPMorgan Chase & Co. boosted their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the company an "overweight" rating in a research report on Tuesday...
MarketBeat·28d ago
<
1
2
...
>

Latest MAZE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.